Myomo's Q2 Beat: 21% Revenue Growth Lifts Guidance, but Can Myomo Hold $1 Stock?

Myomo delivered a cleaner quarter, but the market still sees a speculative story

Myomo's second quarter was clearly better than the prior year. Revenue reached $11.7 million, up 21% year over year, and management raised full-year guidance to $45 million to $47 million from $43 million to $46 million. Still, the stock only moved from a $1.06 regular-session close to $1.11 in after-hours trading. The response was positive, but modest, which suggests investors are still treating Myomo as a volatile turnaround rather than awarding it an outright rerating.

Why the reaction stayed muted

The operating trends improved across several measures: Myomo delivered 211 MyoPro devices, posted 255 units in orders, expanded gross margin, and ended the quarter with 218 patients in backlog. Those are constructive signals. But for the stock to re-rate more decisively, investors likely want to see more than one solid quarter. They also likely want better alignment between business progress and the company's investor base.

Operating leverage was the strongest part of the quarter

The headline beat mattered, but the bigger signal was inside the income statement. Myomo was not just growing revenue; it was doing so with better margin performance and very limited expense growth.

Gross margin expanded while spending stayed contained

Gross margin climbed to 72.1% from 62.7%, and operating expenses rose less than 1%. That combination matters because it suggests Myomo is extracting more value from each device sale rather than funding growth with heavier spending. The guidance raise looks more credible when paired with that kind of operating leverage.

Revenue mix points to a stickier demand pattern

The source of the revenue also improved. Recurring patient sources made up 53% of revenue, up from 26% a year ago. That does not prove durability on its own, but it does point to a more repeatable usage pattern rather than a one-quarter shipment spike.

Channel mix improved as well: US O&P revenue grew 130% and international revenue grew 32%. Myomo also said its clinical referral network and market awareness are helping drive adoption. Taken together, those details support the view that demand may be becoming more structured, not just larger.

Cash flow improved, which matters at this stock price

For a company trading around $1, cash management is still important. Myomo ended Q2 with $13.5 million in cash and short-term investments, and cash used in operating activities improved to $1.9 million from $8.9 million a year earlier. That gives management more flexibility to fund the go-to-market push without immediately turning to the market for capital.

The bull case and bear case both center on execution, not just growth

The next question is whether the guidance raise gives bulls a workable runway or simply sets an easy bar.

Bulls can lean on margin expansion

Myomo is now guiding to Q3 2026 revenue of $11.5 million to $12 million after $11.7 million in Q2, while full-year guidance has moved to $45 million to $47 million. That is not a dramatic jump, and that may be part of the appeal. If revenue keeps progressing while fixed spending stays contained, the path to narrower losses becomes more plausible.

Management also highlighted holding operating expenses roughly flat while growing revenue. That supports the bull case that Myomo does not need heroic growth to narrow losses further; it needs steady execution.

Bears can still point to unresolved risk

The rebuttal is straightforward: Myomo still posted a net loss of $4 million and an adjusted EBITDA loss of $800,000. The business is getting closer to sustainability, but it is not there yet. A guidance raise does not remove that fact.

There is also a credibility risk around timing. Management is asking investors to commit to a full-year outlook before the company has proven it can consistently clear a higher bar. If Q3 comes in near the low end of the range, investors may focus less on the guidance beat and more on whether the ramp is truly strengthening.

What would justify a more durable rerating?

Myomo has clearer operating momentum, with 53% of Q2 revenue from referral network sources. But the stock's level suggests the market has not fully committed to the story yet. That leaves room for a rerating-if the business can keep backing up the narrative.

The next quarter matters more than the post-earnings pop

The next quarterly report is the real test. Myomo's Q3 2026 revenue guidance of $11.5 million to $12 million is specific enough that any weakness would show up quickly in reported results, expense control, and cash use.

What matters most from here: - Whether recurring patient-source revenue stays strong or improves further. - Whether gross margin holds near current levels as volume rises. - Whether operating cash use remains controlled. - Whether future filings show better insider or institutional alignment.

Myomo is still a proof story. The quarter improved the case for the business, but the next few quarters have to show that the improvement is repeatable.